Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Gains from Sales and Divestitures (2024 - 2025)

Historic Gains from Sales and Divestitures for Janux Therapeutics (JANX) over the last 2 years, with Q3 2025 value amounting to $10275.0.

  • Janux Therapeutics' Gains from Sales and Divestitures rose 31100.0% to $10275.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $10275.0, marking a year-over-year increase of 31100.0%. This contributed to the annual value of $2500.0 for FY2024, which is N/A changed from last year.
  • Per Janux Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $10275.0 for Q3 2025, which was up 31100.0% from $2500.0 recorded in Q2 2025.
  • Janux Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $10275.0 during Q3 2025, with a 5-year trough of $2500.0 in Q3 2024.